RxDoctor Payments Data

Vincent Firrincieli, MD

Allergy & Immunology · Raleigh, NCNPI 1952308801

Payments from drug & device makers

$825in general payments, 2019–2025

Across 35 payments — averaging $23.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$271
  • AstraZeneca$135
  • Regeneron Healthcare Solutions, Inc.$120
  • Amgen$77
  • Novartis$61
  • AbbVie$51
  • plus $110 from 5 others

What the payments were for

  • Food & beverage$79196%
  • Education$344%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$825 in reported general payments places this provider in the 20th percentile of 140 allergy & immunology providers in North Carolina.

See all allergy & immunology providers in North Carolina

Medicare billing

Part B allowed, 2024
$187,431
Medicare patients
154
Services billed
7,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab63$177,482
NucalaMepolizumab12$47,900
TezspireTezepelumab-Ekko12$46,618
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$34,742
Breo ElliptaFluticasone/Vilanterol32$20,323
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$16,091
DuleraMometasone/Formoterol33$11,514
Epinephrine31$7,086
Arnuity ElliptaFluticasone Furoate24$5,966
SymbicortBudesonide/Formoterol Fumarate11$4,269
Wixela InhubFluticasone Propion/Salmeterol15$1,763
Albuterol Sulfate HfaAlbuterol Sulfate47$1,276
Levocetirizine Dihydrochloride30$813
Ipratropium Bromide19$772
Ventolin HfaAlbuterol Sulfate14$770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta$271$108,930122 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$135$66,97949 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 140 allergy & immunology providers in North Carolina.

Other allergy & immunology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →